Vivax malaria Infections and Infestations Malaria
Conditions
Interventions
Oral chloroquine 25 mg base/kg over 3 days (10 mg base/kg stat, followed by 10 mg base/kg at 24 hours later, followed by 5 mg base/kg at 48 hours).
Total duration of follow-up is 42 days.
Sponsors
University of Oxford (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Written informed consent from patient or attending relative 2. Age greater than 1 year old, either sex 3. P. vivax infection (greater than 500 asexual stages/µL) 4. Acute uncomplicated malaria (World Health Organization [WHO] 2000) 5. Axillary temperature greater than 37.5°C 6. No full course of antimalarial treatment in the previous 3 days 7. High probability that patient will be able to complete 42 days follow up
Exclusion criteria
Exclusion criteria: 1. Inability or unwillingness to give informed consent 2. Mixed species malaria infections 3. Severe malaria (WHO, 2000) 4. History of allergy to chloroquine 5. Asymptomatic malaria 6. Low probability of 42 days follow up
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cure rate. Outcomes measured daily until parasite clearance and then weekly until 42 days post treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Parasite clearance time 2. Fever clearance time Outcomes measured daily until parasite clearance and then weekly until 42 days post treatment. | — |
Countries
Laos
Outcome results
None listed